{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-045049","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.496804+00:00","generated_at":"2026-05-17T03:46:34.642677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance","bullets":["GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).","Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).","FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).","Adjusted operating margin improved 40bps to 23.0% of sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-045049","json":"https://secwatch.observer/filing/0001628280-25-045049.json","markdown":"https://secwatch.observer/filing/0001628280-25-045049.md","text":"https://secwatch.observer/filing/0001628280-25-045049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/0001628280-25-045049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/abt-20251015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:46:34.642677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}